Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to find out if bacterial load in the airways can be reduced after inhalation of ciprofloxacin for 28 days.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Collaborator: Novartis
• Treatments: Ciprofloxacin

Criteria

Inclusion Criteria:

• Patients with a proven and documented diagnosis of non-cystic fibrosis idiopathic or post pneumonic bronchiectasis

• Stable pulmonary status and stable regimen of standard treatment at least for the past 30 days

Exclusion Criteria:

• Forced Expiratory Volume 1 < 35% or > 80%

• Allergic bronchopulmonary aspergillosis

• Immunodeficiency disease requiring immunoglobulin replacement

• Inflammatory bowel disease